In H1 of both 2024 and 2025, ADC appeared as the leading modality among China-originated drugs that received expedited review programs or filed for INDs. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
